GL1X · GenesisL1 explorer

Research workbench

Crystal structure of small molecule inhibitor TM5484 bound to stabilized active plasminogen activator inhibitor-1 (pai-1-stab)

Analyse Crystal structure of small molecule inhibitor TM5484 bound to stabilized active… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7AQF
Type
protein
Length
736 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Plasminogen activator inhibitor 1
UniProt
P05121
Ligands
RV2
Pockets
9 · best druggability 0.69

Structure

x-ray diffraction · 2 distinct chains · 30% helix, 32% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APlasminogen activator inhibitor 1protein37029% helix, 32% strandP05121
BPlasminogen activator inhibitor 1protein36631% helix, 32% strandP05121

Ligands and binding sites

  • RV2 · 5-Chloro-2-[[2-[3-(furan-3-yl)anilino]-2-oxoacetyl]amino]benzoic acid · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

9 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15430.690.7943empty
21400.630.8627empty
3860.590.8719empty
41450.570.8225empty
52320.530.7741empty

Interfaces

1 interface between chains.

  • A–B · 814 Ų buried · 9 hydrogen bonds · protein-protein

Compared structures

  • 7AQF · Crystal Structure of Small Molecule Inhibitor TM5484 Bound to Stabilized Active… · the same entry in another collection · chain A against A, TM-score 1.00
  • P05121 · AlphaFold monomer V2.0 prediction for plasminogen activator inhibitor 1 (P05121) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.